Adiponectin can reduce the development and progression of several malignancies, such as breast, colon, and lung cancer, through different molecular mechanisms mediated by the recruitment of the adaptor protein APPL1 and the activation of AMPK, mTOR, PI3K/AKT, MAPK, STAT3, and NF-kB pathways [96,98]. Here, ADIPOQ is linked to lung carcinoma.